Comparative Pharmacology
Head-to-head clinical analysis: TIAGABINE HYDROCHLORIDE versus VIGADRONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TIAGABINE HYDROCHLORIDE versus VIGADRONE.
TIAGABINE HYDROCHLORIDE vs VIGADRONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tiagabine inhibits GABA reuptake into presynaptic neurons and glial cells by binding to the GAT-1 GABA transporter, thereby increasing synaptic GABA concentrations and enhancing inhibitory neurotransmission.
Irreversible inhibitor of GABA transaminase (GABA-T), leading to increased brain concentrations of gamma-aminobutyric acid (GABA).
Initial: 4 mg orally once daily; titrate by 4-8 mg/day at weekly intervals. Maintenance: 32-56 mg/day divided 2-4 times daily. Maximum dose: 56 mg/day.
Adults: 500 mg orally twice daily, may increase by 500 mg/day every week; maximum 1500 mg twice daily.
None Documented
None Documented
Terminal half-life of 5–8 hours in healthy adults; prolonged to 12–16 hours in hepatic impairment. Reduces with enzyme-inducing co-medications.
Terminal elimination half-life: 5-7 hours in young adults; 12-15 hours in elderly; therapeutic steady-state achieved within 2-3 days.
Primarily hepatic metabolism via CYP3A4, with <2% excreted unchanged in urine. 63% of dose excreted in feces, 25% in urine as metabolites.
Renal: 70% unchanged; hepatic metabolism: 20% (primarily via CYP4A7, not CYP450); fecal: <5%.
Category A/B
Category C
Anticonvulsant
Anticonvulsant